Purpose: KBD) is an endemic osteoarthropathy which is mainly characterised by the degeneration and necrosis of hyaline articular cartilage. At present the etiology and pathogenesis of KBD is unclear. The aim of this study was to investigate the expression of proteoglycan, hyaluronic acid (HA) receptor CD44 and other factors that regulate cartilage metabolism using the chondrocytes and tissue grafts cultured under in vitro conditions that mimic some of the etiological factors that are thought to be involved in the pathogenesis of KBD. Methods: Different concentrations of mycotoxins suspected as etiological factors causing KBD; i.e. nivalenol (NIV), deoxynivalenol (DON), T-2 toxin, butenolide (BUT) and moniliformin (MON), and Selenium (Se) which is thought to abrogate KBD pathology, were added at physiological concentrations to cultured chondrocytes and artificial cartilage grafts in vitro to establish models of cartilage degeneration and necrosis similar to that found with KBD. In addition, cartilage tissue and blood samples were collected from KBD patients. RT-PCR was used to detect the mRNA expression of CD44, HA synthase (HAS), aggrecan, aggrecanases, matrix metalloproteinases (MMP) and tissue inhibitor of metalloproteinases (TIMPs). Corresponding protein expression was determined using Western blot analyses. Immunohistochemistry was used to study the effects of the mycotoxins on cartilage extracellular matrix metabolism; i.e. neoepitopes for matrix proteinase degradation (BC-3/BC-13 & BC-4/BC-14) and CD44. ELISAs were used to quantify Il-1b, TNF-a, MMPs, soluble CD44 and HA levels in the culture media and KBD patient serum. Results: A decrease of chondrocyte density and a gradual increase in chondrocyte degeneration and necrosis were observed with the increase of mycotoxin concentrations. Se addition partially alleviated this cartilage degradation, but did not change the overall trend of degenerative changes. mRNA expression of aggrecan, TIMP-1 and -3 decreased whilst that of CD44, HAS, aggrecanase-1 and -2, and MMPs increased in chondrocytes cultured with the mycotoxins; Se addition showed some changes. Extracellular matrix staining for cartilage aggrecan became weak and non-uniform but after Se addition this matrix staining improved. The expression of aggrecan specific degradation neoepitopes in cartilage matrix increased in the presence of the mycotoxins, and this was reduced after Se addition. The expression of CD44 on the chondrocyte cell membranes decreased and that in matrix increased in the presence of the toxins. The levels of glucuronic acid, soluble CD44 and HA in cell culture media increased gradually with the increase of mycotoxin concentration. After Se addition, the levels of glucuronic acid showed a decrease, but that of soluble CD44 levels did not change. The levels of Il-1b and TNF-a in the culture media of the toxin groups were higher than Control groups. Conclusions: These in vitro studies have exposed chondrocyte and cartilage graft cultures to conditions of mycotoxin exposure that mimic those believed to be involved in the etiology of KBD patient pathology. Our results indicate that many of the pathogenic and degradation changes observed in KBD patients are expressed in these model in vitro culture systems including the abrogation of some of these effects by adding Selenium. Purpose: Topical treatment of painful muscular and joint complaints with comfrey root ointment has often been questioned in terms of efficacy. However, several randomised controlled trials (RCT) impressively showed the efficacy and safety in blunt injuries and muscle pain of the back. Most recent data confirmed even superiority versus topical diclofenc in acute unilateral ankle sprains. However, more clinical trials were demanded to prove the efficacy in further painful disorders, like osteoarthritis. The aim of this study was to demonstrate the therapeutic efficacy and safety of a comfrey root extract ointment (Extr. Rad. Symphyti) in the treatment of patients with painful osteoarthritis of the knee. Methods: This randomised, double-blind, placebo-controlled study was performed in accordance with the Declaration of Helsinki/Hong Kong 1989/Somerset 1996 as well as ICH-GCP Guidelines. 220 patients (153 women, 67 men, mean age 57.9 years) daily received 6 g (3×2 g) of either an active ointment (Kytta-Salbe ® f, containing comfrey root fluid extract 1:2, 35.0 g) or a corresponding placebo, for 21 days. The active ointment is available in Germany and Switzerland as a Pharmacy (P) OTC drug and in the UK on the General sales list (GSL). Pain, stiffness and functional impairment are the important symptoms patients seek to relieve. Therefore, the primary target variable was the Visual Analog Scale (VAS) sum score of pain at rest and pain on movement. Secondary target variable was the Western Ontario and McMaster Universities (WOMAC) score. All patients met the criteria of the American College of Rheumatology. Baseline characteristics were compared and a statistical analysis was performed and verified that there was no statistical difference between the verum and the placebo group. Results: In the course of the study, the VAS sum score (primary target variable) decreased by 51.6 mm (54.7%) in the active therapy group and by 10.1 mm (10.7%) in the placebo group. The mean group difference of 41.5 mm or 44.0% points was significant (p < 0.001). The WOMAC percentage sum score (secondary target variable) also decreased strongly. At the end of the study, a reduction by 60.4 mm (58.0%) was observed in the active therapy group and by 14.7 mm (14.1%) in the placebo group. The mean group difference of 45.7 mm or 43.9% points was significant (p < 0.001). With regard to the exploratory target variables SF-36 (quality of life), angle measurement (knee mobility), CGI (clinical global impression) and global efficacy assessment by investigator and patient, again a significant superiority was demonstrated (p < 0.001, respectively) for the phytotherapeutic agent versus placebo. 7 patients of the active therapy group were rated as, no longer requiring treatment.
Clinical Aspects/Outcomes

Conclusions:
The verum reduced the symptoms of osteoarthritis of the knee significantly. The therapy lead to reduction of pain, improved knee mobility and better quality of life. Therefore, the present clinical trial has demonstrated that the topical application of a comfrey root extract is a sensible and safe treatment option for patients with painful osteoarthritis. 
Methods:
Patients consulting for non-traumatic knee complaints in general practice aged >35 years were enrolled in the study. At baseline and during one year follow-up knee complaints and function was assessed by 3-monthly questionnaires. A physical examination was performed at baseline and after one year follow-up. The prognostic value of fulfilling the
